Clinical study of rociverine tablets combined with Suoquan capsules in the treatment of female patients with overactive bladder syndrome
10.3760/cma.j.issn.1008-6706.2016.14.014
- VernacularTitle:罗西维林联合缩泉胶囊治疗女性膀胱过度活动症的临床研究
- Author:
Dongwei YAO
;
Cheng LIU
;
Xuejun LIU
;
Duo LIU
;
Jiagui MU
;
Dongsheng ZHU
;
Li FAN
- Publication Type:Journal Article
- Keywords:
Overactive bladder;
Rociverine;
Suoquan capsules;
Efficacy
- From:
Chinese Journal of Primary Medicine and Pharmacy
2016;23(14):2130-2133,2134
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the efficacy and safety of combining rociverine tablets with Suoquan cap-sules in the treatment of female patients with overactive bladder(OAB).Methods 152 female patients with OAB were randomly divided into three groups.Patients in rociverine group were administered rociverine tablets 10mg three times a day for 4 weeks.Patients in Suoquan capsule group were administered Suoquan capsules 1.8g three times a day for 4 weeks.Patients in combination group were administered rociverine tablets 10mg and Suoquan capsule 1.8g three times a day for 4 weeks.Each group of patients had to complete 3d voiding diary before and after treatment to record daily frequency of micturition,urgency,urgency incontinence,nocturia and avoiding volumes,OABSS score and drug side effects were also observed.All the data were analyzed to assess the efficacy and safety of treatment.Results There were significant differences in daily frequency of micturition,urgency,urgency incontinence,nocturia,avoiding volumes and OABSS score of patients in each group before and after treatment(all P <0.01 ).Moreover,compared with combination group,rociverine and Suoquan capsule group all had significant differences(F =41.765,53.834, 25.304,37.867,214.791,73.486,all P <0.01 ).There was no significant differences between rociverine and Suoquan capsule group(all P >0.05).The incidence rates of adverse events of rociverine and combination group were 7.8% and 22.6%,respectively,there was significant difference between the two groups(χ2 =4.372,P =0.032). Conclusion Combining rociverine tablets with Suoquan capsules in the treatment of female patients with OAB was effective and safe.
